MA42613A - Filtration en profondeur chargée de protéines de liaison à un antigène - Google Patents

Filtration en profondeur chargée de protéines de liaison à un antigène

Info

Publication number
MA42613A
MA42613A MA042613A MA42613A MA42613A MA 42613 A MA42613 A MA 42613A MA 042613 A MA042613 A MA 042613A MA 42613 A MA42613 A MA 42613A MA 42613 A MA42613 A MA 42613A
Authority
MA
Morocco
Prior art keywords
antigen binding
binding protein
deep filtration
loaded
filtration loaded
Prior art date
Application number
MA042613A
Other languages
English (en)
Inventor
Rafael Gonzalez
Hai Hoang
Junfen Ma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA42613A publication Critical patent/MA42613A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA042613A 2015-08-13 2016-08-12 Filtration en profondeur chargée de protéines de liaison à un antigène MA42613A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13

Publications (1)

Publication Number Publication Date
MA42613A true MA42613A (fr) 2018-06-20

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042613A MA42613A (fr) 2015-08-13 2016-08-12 Filtration en profondeur chargée de protéines de liaison à un antigène

Country Status (15)

Country Link
US (3) US11098079B2 (fr)
EP (3) EP4470648A3 (fr)
JP (1) JP6889149B2 (fr)
DK (2) DK3334747T5 (fr)
ES (2) ES2964640T3 (fr)
FI (2) FI3334747T3 (fr)
HR (2) HRP20241510T1 (fr)
HU (2) HUE064252T2 (fr)
LT (2) LT3334747T (fr)
MA (1) MA42613A (fr)
PL (1) PL3334747T3 (fr)
PT (2) PT3334747T (fr)
SG (1) SG10202101105XA (fr)
SI (2) SI4209499T1 (fr)
WO (1) WO2017027861A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877589B1 (fr) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN107973487B (zh) * 2017-11-14 2021-03-02 东华大学 一种染整废水层级处理工艺及装置
CN114981286B (zh) 2019-05-03 2026-02-13 豪夫迈·罗氏有限公司 降低从纯化平台获得的组合物中酶水解活性速率的方法
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
EP4090666A1 (fr) 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Procédés de réduction d'impuretés à partir de procédés de fabrication de protéines recombinantes
WO2021158469A1 (fr) * 2020-02-03 2021-08-12 Amgen Inc. Approche d'encadrement à plusieurs variables pour la validation d'un filtre stérile
CN111410688A (zh) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 一种提高双特异性抗体纯度的分离纯化方法
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022251253A1 (fr) 2021-05-24 2022-12-01 Provention Bio, Inc. Méthodes de traitement du diabète de type 1
WO2025252480A1 (fr) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Procédé de purification d'adn plasmidique

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2451955C (fr) 2001-06-26 2015-09-29 Abgenix, Inc. Anticorps opgl
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
KR20110086881A (ko) 2002-12-20 2011-08-01 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
MEP31508A (hr) 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade
JP4746552B2 (ja) 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
EP1712240B1 (fr) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Preparation medicamenteuse aqueuse stable contenant un anticorps
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
WO2007035283A1 (fr) 2005-09-15 2007-03-29 Wyeth Floculation de proteines au moyen de sels
JP2010510963A (ja) 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
EP2089431A4 (fr) 2006-10-19 2010-03-17 Tolerx Inc Procedes et compositions pour l'elimination efficace de la proteine a de preparations de molecules de liaison
HUE037162T2 (hu) * 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
DE102008037678A1 (de) 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
HUE053480T2 (hu) * 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
EP2490780A4 (fr) 2009-10-20 2014-04-09 Merck Sharp & Dohme Utilisation de la chromatographie en mode mixte pour la capture et la purification de produits d'anticorps de base
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011140405A1 (fr) * 2010-05-07 2011-11-10 Millipore Corporation Milieu de clarification amélioré
NZ603616A (en) 2010-05-18 2015-02-27 Abbvie Inc Apparatus and process of purification of proteins
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
CA2815342A1 (fr) 2010-10-20 2012-04-26 Medimmune, Llc Methodes de traitement de corps d'inclusion
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US9534037B2 (en) 2011-08-02 2017-01-03 Baxalta GmbH Systems and methods to increase protein yield from recombinant manufacturing processes
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
TW201348246A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (fr) * 2012-07-02 2014-01-08 Millipore Corporation Dispositif de tirage et métier à filer
JP6553515B2 (ja) 2012-12-20 2019-07-31 メディミューン，エルエルシー 免疫複合体の製造方法
CA2899449A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Composition d'especes faiblement acides et leurs methodes de production utilisant la chromatographie de deplacement
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
ES2834113T3 (es) 2013-03-15 2021-06-16 H Lundbeck As Purificación de anticuerpos y monitorización de la pureza
WO2014196926A1 (fr) 2013-06-04 2014-12-11 Agency For Science, Technology And Research Procédé de purification de protéine
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
SG11201509390TA (en) 2013-08-30 2015-12-30 Emd Millipore Corp High capacity composite depth filter media with low extractables
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
EP3066123A1 (fr) * 2013-11-07 2016-09-14 AbbVie Inc. Isolement et purification d'anticorps
CN106164086A (zh) 2014-02-27 2016-11-23 新加坡科技研究局 抗体纯化方法
EP3119871A4 (fr) 2014-03-17 2018-01-03 Regeneron Pharmaceuticals, Inc. Clarification de culture cellulaire de mammifère
EP3145951A1 (fr) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
US20160176921A1 (en) * 2014-12-22 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène

Also Published As

Publication number Publication date
JP6889149B2 (ja) 2021-06-18
EP4470648A3 (fr) 2025-03-05
PT3334747T (pt) 2023-12-12
FI3334747T3 (fi) 2023-11-30
DK4209499T3 (da) 2024-11-11
EP4209499A1 (fr) 2023-07-12
HRP20231544T1 (hr) 2024-03-15
PL3334747T3 (pl) 2024-04-02
HUE064252T2 (hu) 2024-02-28
EP4209499B1 (fr) 2024-08-07
FI4209499T3 (fi) 2024-11-05
US20250230187A1 (en) 2025-07-17
US11098079B2 (en) 2021-08-24
DK3334747T3 (da) 2023-12-11
SG10202101105XA (en) 2021-03-30
WO2017027861A1 (fr) 2017-02-16
HUE069195T2 (hu) 2025-02-28
US20210363180A1 (en) 2021-11-25
PT4209499T (pt) 2024-11-08
DK3334747T5 (da) 2024-10-07
LT4209499T (lt) 2024-11-25
EP3334747B1 (fr) 2023-09-27
SI3334747T1 (sl) 2024-02-29
HRP20241510T1 (hr) 2025-01-03
ES2964640T3 (es) 2024-04-08
SI4209499T1 (sl) 2025-01-31
ES2995985T3 (en) 2025-02-11
EP3334747A1 (fr) 2018-06-20
JP2018526357A (ja) 2018-09-13
US20180230180A1 (en) 2018-08-16
EP4470648A2 (fr) 2024-12-04
LT3334747T (lt) 2023-12-27

Similar Documents

Publication Publication Date Title
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL265321B1 (en) Cd3 binding antibodies
IL263840A (en) Cd3 binding antibodies
IL257798A (en) Anti-lag-3 antibodies
EP3352760A4 (fr) Polypeptides de liaison à cd3
IL254516A0 (en) Proteins specific for cd137
EP3538557A4 (fr) Anticorps anti-cd47
DK3242892T3 (da) Modificerede april-bindende antistoffer
IL258448B1 (en) Antigen-binding proteins that activate the leptin receptor
RS67851B1 (sr) Proteini koji vezuju anti-tl1a antigen i njihova primena
EP3319984C0 (fr) Anticorps de liaison tau
IL246921B (en) Binding proteins and methods of use thereof
HUE054616T2 (hu) Immunmodulátor fehérjék hangolható affinitásokkal
HRP20260348T1 (hr) Antitijela koja vezuju tau
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3506964A4 (fr) Seringue contraignante
EP3680332C0 (fr) Système de préparation d'échantillons et cartouche
DK3325514T3 (da) Her2-bindende proteiner baseret på di-ubiquitin-muteiner
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
DK3512886T3 (da) Antigenbindingsprotein mod her3
IL259181A (en) Opposite ph-salt gradients for improved protein separations
DK3484921T3 (da) Anti-IL-22R antistoffer